MedPath

Estimation of usefulness of intravenous admnistration of alendoronate for bone disorders after gastrectomy

Phase 2
Conditions
Distrubances of bone tissue metabolism
Registration Number
JPRN-UMIN000012143
Lead Sponsor
Yokohama City University Medical Center
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
46
Inclusion Criteria

Not provided

Exclusion Criteria

1. Patients with some diseaes which may be worse by the participation of this study. 2. Pregnant patients or patients who hope pregnancy 3. Patients who are judged inappropriate by doctors

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Bone mineral density (L1-4)
Secondary Outcome Measures
NameTimeMethod
1. Bone mineral density of the total hip 2. Bone turnover markers (serum BAP, serum NTx, Serum TPACP-5b) 3. Adverse effect
© Copyright 2025. All Rights Reserved by MedPath